Key result
CYP2C19*17 allele linked to ~22-fold higher bleeding risk, while *2 or *3 alleles predict major cardiovascular events.
Why the study?
Data on genetic and nongenetic factors affecting clopidogrel response in the Arab population are scarce.
Does the presence of CYP2C19 genetic variants affect the risk of bleeding and MACE in Arab patients undergoing PCI and receiving clopidogrel?
Cohort (n=254)
No
Does the presence of CYP2C19 genetic variants affect the risk of bleeding and MACE in Arab patients undergoing PCI and receiving clopidogrel?
Answers are grounded in this paper and cite their sources.
In Arab patients undergoing PCI and receiving clopidogrel, the CYP2C19*17 allele is strongly associated with increased bleeding risk, while the *2 and *3 alleles are associated with increased MACE risk.
INTRODUCTION: One-third of patients have clopidogrel resistance that may lead to major adverse cardiac events (MACEs). By contrast, it was found that some clopidogrel-treated patients have hyperresponsive platelets that are associated with higher bleeding risk. Several studies have shown that polymorphisms in the gene encoding the CYP2C19 contribute to the variability in response to clopidogrel. Data on genetic and nongenetic factors affecting clopidogrel response in the Arab population are scarce. In this prospective cohort study, we sought to assess the association between the increased function allele (CYP2C19*17) and bleeding events, and validate the effect of the CYP2C19 genetic variants and nongenetic factors on the incidence of MACEs. METHODS: Blood samples were collected from patients that were undergoing percutaneous coronary intervention and receiving clopidogrel at the Heart Hospital, a specialist tertiary hospital in Doha, Qatar. Patients were followed for 12 months. Genotyping was performed for CYP2C19*2, *3, and *17 using TaqMan assays. RESULTS: In 254 patients, the minor allele frequencies were 0.13, 0.004, and 0.21 for *2, *3, and *17, respectively. Over a 12-month follow-up period, there were 21 bleeding events (8.5 events/100 patient-year). CYP2C19*17 carriers were found to be associated with increased risk of bleeding (OR, 21.6; 95% CI, 4.8-96.8; P < 0.0001). CYP2C19*2 or *3 carriers were found to be associated with increased risk of baseline and incident MACE combined (OR, 8.4; 95% CI, 3.2-23.9; P < 0.0001). CONCLUSION: This study showed a significant association between CYP2C19*17 allele and the increased risk of bleeding, and CYP2C19*2 or *3 with MACE outcomes.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2022) conducted a cohort in Percutaneous coronary intervention (n=254). CYP2C19*17 allele vs. Non-carriers was evaluated on Bleeding events (OR 21.6, 95% CI 4.8-96.8, p=< 0.0001). Carriage of the CYP2C19*17 allele was associated with an increased risk of bleeding, while CYP2C19*2 or *3 alleles were associated with increased major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: